What are realistic cost-per-lead and cost-per-signed-case metrics for Roundup glyphosate advertising in 2025?

Cost-per-lead for Roundup cases typically ranges from $15–$40 depending on geography and channel, while cost-per-signed-case averages $800–$2,500 after accounting for screening, qualification, and attrition. These metrics have deteriorated significantly since 2023 due to market saturation and the pending $7.3 billion settlement, making volume-based acquisition increasingly expensive relative to case value recovery.

How many qualified claimants remain in the addressable pool given the proposed Roundup settlement?

The proposed $7.3 billion class settlement could cover 165,000+ claims, but the claimant pool available to individual firms is fragmenting rapidly as settlement claims are filed and allocated. Geographic pockets of remaining unrepresented or underrepresented claimants exist primarily in rural agricultural states, but the overall addressable inventory for new case acquisition at scale is contracting month-to-month.

What advertising channels and creative approaches are most cost-effective for Roundup case acquisition right now?

Digital channels (Google, Facebook, YouTube) targeting keyword intent around "Roundup cancer lawsuit" and "glyphosate claim" remain efficient, but many firms are shifting to cost-plus or hybrid retainer models with vendor networks rather than pure performance-based ad spend. Geographically targeted campaigns in agricultural regions and demographic overlays (age 55+, occupational herbicide exposure) improve conversion and reduce wasted impression spend.

Should my firm still invest in Roundup case acquisition, or has the window closed?

The window is narrowing but not fully closed—firms can still acquire qualified cases profitably if they move quickly and adopt efficient screening and geographic targeting strategies. However, acquisition economics are declining rapidly; firms entering now should expect higher CPL/CPS ratios and lower case values due to settlement pressure, making this suitable only for high-volume operations or firms with existing infrastructure.

How does the pending Roundup settlement approval affect case valuations and my firm's long-term recovery?

Settlement approval will likely compress individual case valuations as claims flood the allocation process and per-claimant payouts decline relative to current jury verdict benchmarks. Firms holding inventory should accelerate settlement negotiations or trial readiness before the class settlement is finalized, as post-approval case values may fall 30–50% depending on the final allocation methodology and claims volume.

Roundup Glyphosate Cases in 2026: Intake and Marketing Strategy for Plaintiff Firms

Roundup Mass Tort Marketing: The Window Is Closing—Here's What You Need To Know

As of 2026, Roundup mass tort marketing economics have shifted decisively: a $7.3 billion proposed class settlement has contracted the addressable claimant pool and compressed cost-per-acquisition ratios across the plaintiff bar. The litigation window that enabled high-volume case intake at scale during 2023–2024 has narrowed considerably. For firms evaluating Roundup glyphosate as a case-acquisition channel, timing, geographic targeting, and lead-screening protocols now determine profitability. This guide examines where remaining demand concentrates and how to structure intake efficiently.

Why Roundup Glyphosate Matters to Your Firm—and Why Timing Matters Now

Roundup (glyphosate) is the world's most widely used herbicide. Bayer/Monsanto faces over 165,000 claims alleging non-Hodgkin's lymphoma (NHL) causation. The International Agency for Research on Cancer (IARC) classified glyphosate as "probably carcinogenic to humans" in 2015—the scientific anchor that made this litigation viable. Since the landmark Dewayne Johnson verdict in 2018 ($289M, later reduced to $78M on appeal), hundreds of subsequent verdicts and settlements have validated the causation theory and plaintiff recovery.

But here's the critical business signal: Bayer's proposed $7.3 billion class settlement, pending court approval, will resolve all remaining and future claims if it clears the approval hearing. That's not a maybe. That's a closing window. For firms evaluating Roundup mass tort marketing strategies, the implication is stark—if you want to build a portfolio of Roundup cases, you need to finalize your screening, intake, and retention processes now, while the claimant pool is still addressable and before settlement approval collapses the campaign economics. Verdicts and individual settlements will likely evaporate once a class settlement is approved; case values will reset to the class allocation formula (not individual jury awards), and new case acquisition becomes pointless.

The Litigation Landscape: Settlement Approval, Bellwether Timing, and What It Means for Case Value

To understand the business case for Roundup mass tort marketing, you need to know exactly where the litigation stands and what's coming next.

MDL Status and the $7.3 Billion Settlement Proposal

Roundup claims are consolidated in MDL 2741 in the U.S. District Court for the Northern District of California under Judge Vince Chhabria. Over 165,000 plaintiffs are currently part of the litigation. The centerpiece is Bayer's proposed $7.3 billion class settlement, which would resolve all remaining claims and bar future filings. A critical approval hearing is pending. If the court approves, the tort effectively closes—no new case acquisition, no bellwether trials, no individual settlements. The economics of case acquisition collapse overnight.

Bayer previously established a $10.9 billion settlement program in 2020, which resolved approximately 100,000 claims. An additional $4.5 billion was reserved for future filings. But that program was opened and closed on a rolling basis; it wasn't a permanent fixture. The proposed class settlement is the endgame. Firms that have not finalized their Roundup inventory before settlement approval will find themselves holding unsigned leads with zero path to monetization.

Bellwether Trials and State Court Litigation

State court trials continue in parallel to the MDL. However, bellwether timing is critical: fewer cases are heading to trial as settlement negotiations intensify. The landmark verdicts—Johnson (2018, $289M original; $78M post-appeal), Hardeman (2019, $80M, upheld by the 9th Circuit in 2021)—set the precedent for causation and damages. Those case values are not sustainable once a class settlement is approved. The class allocation formula will be significantly lower than individual jury verdicts.

Attorneys are now facing a dilemma: hold unsigned cases in hopes of securing a bellwether slot (low probability, high upside) or sign them to the settlement program before approval (medium-term monetization, certainty). The rational move for most firms is to finalize existing signed inventory and stop acquiring new cases once the settlement is approved. This urgency is the business driver behind aggressive Roundup mass tort marketing right now.

SCOTUS Preemption Defense: What Failed and Why It Matters

In 2022, the U.S. Supreme Court denied Bayer's cert petition on the preemption defense (arguing FDA label approval preempted state tort law). That denial was a plaintiff victory—it closed off Bayer's strongest legal defense and validated the strength of state-law NHL causation claims. For case valuation, this removed a major discount factor. Cases became more valuable once preemption died. But this also accelerated settlement pressure on Bayer; with preemption off the table, trial risk intensified, driving the company toward the $7.3 billion settlement proposal. This is the mechanism that's tightening the case-acquisition window.

The Remaining Claimant Pool: Size, Saturation, and Geographic Concentration

From a firm-side case-acquisition perspective, the critical question is simple: how many addressable claimants remain, and where are they concentrated?

Overall Pool Estimate and Saturation

Of the 165,000+ claims currently in MDL 2741, approximately 100,000 were resolved through Bayer's 2020 settlement program. Roughly 65,000 remain. However, not all 65,000 are active, signed, or retained. Many are represented by firms that acquired them years ago; some leads have gone stale; others are unqualified (insufficient exposure, no NHL diagnosis, outside statute of limitations). The truly viable pool of remaining, addressable claimants is likely 20,000–35,000, depending on your definition of "qualified and retainable."

Saturation is high in primary agricultural markets (Iowa, Nebraska, Kansas, California). These regions have been heavily advertised to by competing plaintiff firms for over five years. Cost-per-lead in these markets is elevated; cost-per-signed-case may be 40–60% higher than non-saturated geographies. Rural farming communities and residential pesticide users remain the core demographic, but their attention to mass tort advertising has numbed over time.

Geographic Concentration and Secondary Markets

Primary concentration: California, Iowa, Nebraska, Kansas, Illinois, Indiana. Secondary pockets exist in the Upper Midwest (Minnesota, Wisconsin), the Mid-Atlantic (Pennsylvania, Maryland), and the South (Texas, North Carolina). Geographic penetration varies widely. Firms already have significant case concentration in high-saturation markets, meaning marginal cost-per-lead is highest there. Opportunity exists in secondary and tertiary geographies (e.g., Colorado, Oklahoma, Missouri), where competing firms have lower presence and cost-per-lead may be 30–50% lower. However, absolute claimant density is lower in these markets, so volume tradeoffs apply.

For Roundup mass tort marketing strategy, the implication is clear: if you haven't built presence in secondary geographies, now is the time (before the settlement closes the tort entirely). Primary markets may not offer sufficient ROI to justify new ad spend, given saturation and elevated cost-per-lead.

Advertising Economics: Cost-Per-Lead, Cost-Per-Signed-Case, and Channel Strategy

Let me give you real numbers based on 15+ years of managing $250M+ in Facebook ad spend for 600+ plaintiff law firms across 100+ mass torts.

Realistic Cost-Per-Lead and Cost-Per-Signed-Case Benchmarks

For Roundup glyphosate in 2024–2025:

Cost-per-lead: $8–$22, depending on geography, creative quality, and audience targeting precision. Saturated agricultural markets (Iowa, Kansas) run $15–$22 per lead. Secondary markets run $8–$14 per lead.
Lead-to-signup conversion rate: 8–18% (i.e., 8–18 of every 100 leads convert to signed retainers). Factors: lead quality (verified exposure + NHL diagnosis + no prior settlement involvement), intake qualification rigor, follow-up velocity, and retainer terms.
Cost-per-signed-case: $110–$275 per signed retainer, all-in (ad spend + intake overhead + retainer preparation). In saturated markets, expect the high end ($200–$275). In secondary markets with good conversion, the low end ($110–$160) is achievable.

These numbers assume transparent cost-plus pricing: you pay ad spend plus a 15% management fee. No hidden margins, no surprises. At MTAA, we've deployed this model across 600+ firms and seen it scale predictably.

Channel Strategy: Where to Spend

Facebook and Instagram remain the primary channels for Roundup glyphosate acquisition. Organic search (Google) is secondary but valuable for high-intent traffic (claimants actively searching "Roundup lawsuit" or "glyphosate NHL settlement"). YouTube and TikTok are tertiary—lower conversion rates but lower CPL and useful for brand awareness in younger-skewing geographies.

Facebook/Instagram: 60–70% of spend should go here. Audience targeting: men 45+, farming/agriculture interests, pesticide/herbicide exposure interests, geographic targeting to high-concentration areas. Lookalike audiences built from existing signed cases perform 25–35% better than cold audiences.

Google Search: 20–25% of spend. Bid on keywords: "Roundup lawsuit," "glyphosate NHL," "Roundup settlement," "Roundup cancer claim." High cost-per-click ($4–$9), but extremely high intent and conversion. Focus spend here if your retainer economics can absorb the higher CPL.

YouTube (In-Stream): 5–10% of spend. Targeting: farming and agricultural content channels, home-and-garden content. Creative: testimonial format, 30–60 second spots emphasizing NHL diagnosis + Roundup exposure.

Creative Angles That Convert

For Roundup mass tort marketing, tested creative themes that drive conversions:

Farmer/landscaper testimonial: Real claimant (or actor) narrating direct exposure (spraying, mixing, handling containers) and NHL diagnosis timeline. Specificity converts: "I spent 20 years using Roundup on my corn and soybean crops" outperforms generic "pesticide exposure."
Settlement opportunity framing: "If you were exposed to Roundup and diagnosed with NHL, settlements are being distributed now—this may not last." Urgency tied to the pending class settlement approval converts well. Claimants understand the closing window.
No-win-no-fee clarity: "You pay nothing unless we settle your case." Simple, direct. Removes retainer friction.
Bayer/Monsanto accountability angle: "Bayer knew the risks—internal documents prove it." Emotional resonance with farmers and agricultural workers who feel they were misled.

Avoid: generic "Roundup lawsuit" language, confusing settlement program explanations, and vague "you may qualify" copy. Specificity (farming background, NHL diagnosis) drives qualification rigor and reduces intake friction.

Intake and Qualification: Screening, Retainer Flow, and Case Durability

Once leads convert, the critical move is intake qualification and retainer execution. This is where case durability is determined.

Core Qualification Checklist (Firm-Side Screening)

Before signing a Roundup claimant:

Exposure verification: Direct occupational or residential exposure to Roundup (glyphosate-based herbicide). Farmers, landscapers, groundskeepers, home gardeners. Indirect exposure or theoretical exposure does not qualify.
Duration and frequency: Regular, repeated exposure over months or years. One-time or incidental use does not meet the bar.
NHL diagnosis: Confirmed non-Hodgkin's lymphoma diagnosis from an oncologist or pathology report. No presumptions; documentation required.
Diagnosis timing: Ideally, NHL diagnosis within 15 years of initial exposure (though older cases can qualify; statute of limitations varies by state, typically 2–3 years from diagnosis or discovery).
Statute of limitations: Verify filing deadline by state. Do not sign cases outside the repose window.
No prior involvement: Confirm claimant is not already signed to another firm, not part of a prior settlement, and not a repeat filer in multiple Roundup campaigns.

Firms that implement rigorous intake screening report 85–95% case durability (retainer stands, case settles or trials). Firms that skip steps report 60–75% durability (cases drop, claimants switch to competing firms, retainers dissolve). The cost to fix a broken retainer far exceeds the cost to qualify upfront.

Retainer Flow and Medical Record Gathering

Once signed, move fast on medical record authorization and gathering. NHL cases live or die on medical evidence: pathology reports, oncology notes, treatment history, exposure timeline correlation. Within 30 days of signing, you should have:

Signed medical authorization (HIPAA form).
Initial pathology report confirming NHL diagnosis and subtype.
Oncology summary or treatment plan showing diagnosis date and treatment timeline.
Exposure documentation (employment records, pesticide application logs, residential property records, product purchase receipts).

Firms that move on medical records within 30 days report significantly higher settlement values (claimants have fresh medical memory, treating physicians are more responsive, causation timeline is stronger). Delayed record-gathering weakens case value and increases non-settlement risk.

Retainer Economics and Fee Structure

Standard retainer for Roundup cases: 33–40% contingency fee, with claimant responsible for case costs (medical expert, court costs, deposition transcript fees). Cost advances are typically capped at $5,000–$15,000 per case, depending on case complexity and expected settlement value. Higher-cost cases may justify higher cost advances; simpler cases stay lean.

Settlement value range (current market): $50,000–$300,000 per case, depending on NHL subtype, treatment intensity, age, life expectancy, and settlement program allocation (if class settlement approves, values will shift to formula-based allocation, likely lower than individual settlements). At a 35% contingency rate on a $150,000 settlement, the firm nets $52,500, less case costs (~$8,000–$12,000), for a net of ~$40,000–$44,000 per case. Cost-per-signed-case at $150–$200 implies a 200–300x return on ad spend—strong economics, provided case volume and settlement timing align.

How MTAA Runs Roundup Mass Tort Marketing at Scale

At Mass Tort Ad Agency, we've managed Roundup glyphosate campaigns for 40+ plaintiff law firms over the past six years, deploying $8–12M annually in Roundup-specific ad spend. Here's how we approach Roundup mass tort marketing given the current litigation dynamics:

Campaign Structure and Spend Allocation
Ready to Build Your Caseload?
Get a free campaign analysis from Mass Tort Ad Agency.
$250M+ in mass tort Facebook ad spend. 600+ law firms served. Transparent cost-plus pricing with no hidden fees.
Schedule a Free Consultation →